Human neutrophil gelatinase-associated lipo- calin (NGAL) is a glycoprotein present in a wide variety of tissues and cell types. It exists as a monomer of 25 kDa, a homodimer of 45 kDa or a heterodimer of 135 kDa (disulfide bound to latent matrix metalloproteinase-9). NGAL is consid- ered the biochemical gold standard for the early diagnosis of acute kidney injury and has attracted much attention as a diag- nostic biomarker. NGAL has controversial (i.e. both beneficial and detrimental) effects on cellular processes associated with tumor development, such as cell proliferation, survival, migration, invasion and drug resistance. Therefore, the present review aimed at clarifying the role of NGAL in renal cell carcinoma (RCC). Relevant studies of NGAL and RCC were searched in PubMed and relevant information about the struc- ture, expression, function and mechanism of NGAL in RCC were summarized. Finally, the following conclusions could be drawn from the literature: i) NGAL can be detected in cancer tissues, serum and urine of patients with RCC; ii) NGAL is not a suitable diagnostic marker for early screening of RCC; iii) NGAL expression may be used to predict the prognosis of patients with RCC; and iv) Further research on NGAL may be helpful to decrease sunitinib resistance and find new treatment strategies for RCC.
CITATION STYLE
Che, K., Han, W., Zhang, M., & Niu, H. (2021, February 1). Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma (Review). Oncology Letters. Spandidos Publications. https://doi.org/10.3892/ol.2020.12409
Mendeley helps you to discover research relevant for your work.